Chen Kaining, Luo Xilian, Zhou Huazhong, Fu Lanyan, Lu Zhaojin, Wang Chenlu, Lin Yueling, Yu Hongyan, Xu Yufen, Pi Lei, Che Di, Wang Zhouping, Gu Xiaoqiong
Department of Clinical Biological Resource Bank, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510620, China.
Department of Cardiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, China.
Heliyon. 2024 Mar 12;10(6):e27699. doi: 10.1016/j.heliyon.2024.e27699. eCollection 2024 Mar 30.
Kawasaki disease (KD) is a condition characterized by acute multi-system vasculitis and high fever in infants and children. Intravenous immunoglobulin (IVIG) is the established therapeutic approach of KD,foralleviating inflammation and mitigate the risk of arterial wall dilation and the development of coronary artery aneurysms (CAA). But almost 20% of the patients developed resistance to IVIG and displayed persistent fever after standard primary treatment. , belonging to the Tetraspanin family, has been demonstrated to modulate innate immunity in a range of human diseases. It accomplishes this by engaging with integrins and actively participating in the process of infection recognition. However, its relevance to susceptibility and IVIG therapy response of KD was unexposed. In the present study, our Integrative analysis of KD transcriptomic data and GTEx data revealed that the eQTL rs12504972 might modify the downregulation of in KD patients. Moreover, our findings suggest a potential association between /rs12504972 and an elevated susceptibility as well as IVIG resistance among patients with Kawasaki disease in southern China. The results provided a new insight that triggered KD susceptibility and resistance of IVIG therapy on the genomic level.
川崎病(KD)是一种以婴幼儿急性多系统血管炎和高热为特征的疾病。静脉注射免疫球蛋白(IVIG)是已确立的KD治疗方法,用于减轻炎症并降低动脉壁扩张和冠状动脉瘤(CAA)发生的风险。但近20%的患者对IVIG产生耐药性,在标准初始治疗后仍持续发热。 ,属于四跨膜蛋白家族,已被证明在一系列人类疾病中调节固有免疫。它通过与整合素结合并积极参与感染识别过程来实现这一点。然而,其与KD易感性和IVIG治疗反应的相关性尚未明确。在本研究中,我们对KD转录组数据和GTEx数据的综合分析表明,eQTL rs12504972可能会改变KD患者中 的下调。此外,我们的研究结果表明, /rs12504972与中国南方川崎病患者易感性升高以及IVIG耐药性之间可能存在关联。这些结果提供了一个新的见解,即 在基因组水平上引发了KD易感性和IVIG治疗耐药性。